$180 Million is the total value of Prosight Management, LP's 34 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 44.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $17,571,000 | -9.3% | 128,000 | -22.2% | 9.75% | -0.3% |
| BMY | Sell | BRISTOL-MYERS SQUIBB CO | $15,461,000 | -16.9% | 304,900 | -25.7% | 8.58% | -8.6% |
| HNGR | Sell | HANGER INC | $8,050,000 | -14.5% | 395,000 | -19.7% | 4.46% | -6.0% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $7,467,000 | -22.5% | 163,133 | -0.7% | 4.14% | -14.7% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $6,300,000 | -35.8% | 346,149 | -13.5% | 3.50% | -29.3% |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $6,011,000 | -24.6% | 2,515,072 | -1.3% | 3.33% | -17.1% |
| ALBO | Sell | ALBIREO PHARMA INC | $5,050,000 | -38.2% | 252,500 | -0.3% | 2.80% | -32.0% |
| RETA | Sell | REATA PHARMACEUTICALS INC-Acl a | $5,025,000 | -57.4% | 62,591 | -49.9% | 2.79% | -53.1% |
| FIXX | Sell | HOMOLOGY MEDICINES INC | $2,775,000 | -61.6% | 153,303 | -58.5% | 1.54% | -57.7% |
| TLGT | Sell | TELIGENT INC | $2,323,000 | +24.2% | 2,446,043 | -17.6% | 1.29% | +36.7% |
| CI | Sell | CIGNA CORP | $1,670,000 | -66.1% | 11,000 | -64.8% | 0.93% | -62.7% |
| UROV | Sell | UROVANT SCIENCES LTD | $972,000 | -13.8% | 102,657 | -28.0% | 0.54% | -5.3% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $924,000 | -38.5% | 2,366,707 | -11.7% | 0.51% | -32.2% |
| MLND | Sell | MILLENDO THERAPEUTICS INC | $370,000 | -56.7% | 52,051 | -29.5% | 0.20% | -52.4% |
| AQXP | Exit | AQUINOX PHARMACEUTICALS INC | $0 | – | -3,637 | -100.0% | -0.01% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -34,224 | -100.0% | -0.13% | – |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -358,963 | -100.0% | -0.30% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -11,000 | -100.0% | -0.36% | – |
| PRSC | Exit | PROVIDENCE SVC CORP | $0 | – | -14,677 | -100.0% | -0.42% | – |
| EOLS | Exit | EVOLUS INC | $0 | – | -112,590 | -100.0% | -0.83% | – |
| Exit | EXACT SCIENCES CORPput | $0 | – | -14,100 | -100.0% | -0.84% | – | |
| ASGN | Exit | ASGN INC | $0 | – | -30,000 | -100.0% | -0.92% | – |
| WCG | Exit | WELLCARE HEALTH PLANS INC | $0 | – | -6,500 | -100.0% | -0.93% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -200,000 | -100.0% | -1.36% | – |
| Exit | INTEC PHARMA LTD JERUSALEM | $0 | – | -815,789 | -100.0% | -1.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.